Protocol Review. The parties agree that before either begins a clinical trial of a Product, whether conducted by or on behalf of such party, it will give the other party the opportunity to review the protocol for such trial, along with the opportunity to provide comments. The reviewing party shall have fourteen (14) days to complete such review. Notwithstanding any such consultation, the party conducting such clinical trial shall maintain full and sole responsibility regarding any such study protocol.
Appears in 3 contracts
Sources: License Agreement (Biosante Pharmaceuticals Inc), License Agreement, License Agreement (Biosante Pharmaceuticals Inc)